Opportunity Information: Apply for PA 09 095
Apply for PA 09 095
- The National Institutes of Health in the education environment food and nutrition health sector is offering a public funding opportunity titled "New Technologies for Liver Disease SBIR (R43/R44)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.113 Environmental Health 93.273 Alcohol Research Programs 93.279 Drug Abuse and Addiction Research Programs 93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research.
- This funding opportunity was created on Feb 11, 2009 and posted on Feb 11, 2009.
- Applicants must submit their applications by Jan 7, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The New Technologies for Liver Disease SBIR (R43/R44) opportunity (Funding Opportunity Number PA 09 095) is a National Institutes of Health (NIH) Small Business Innovation Research (SBIR) grant program designed to bring small businesses into the pipeline of creating practical, high-impact innovations for liver disease. At its core, the FOA is looking for SBIR proposals that translate scientific and engineering advances into usable products or enabling technologies that improve how liver diseases are detected, tracked, treated, and ultimately prevented. Rather than focusing on basic research alone, the announcement emphasizes development-oriented work that can produce tangible tools, methods, or therapeutics that meaningfully address clinical and public health needs in liver disease.
The scope is broad and intentionally flexible, covering the development of resources, research tools, instrumentation, biomarkers, devices, drugs, and other novel approaches that improve diagnosis, monitoring, management, treatment, or prevention of liver diseases. Priority interest areas called out in the description include reliable and practical diagnostic methods and biomarkers that reflect disease activity and stage. The FOA also highlights noninvasive testing approaches, particularly for measuring inflammation, fibrosis (scarring), and fat in the liver, which are key features across many liver conditions and major drivers of outcomes. On the intervention side, the opportunity supports development of drugs and other therapeutic strategies, including biologics and molecular reagents, as well as complementary and alternative modalities, provided the work is positioned as a credible development effort aimed at therapy or prevention.
A major stated goal is to mobilize the small business research community to advance tools and interventions that align with the trans-NIH Action Plan for Liver Disease Research. In practice, that means applications are expected to fit into a larger national research strategy: generating better diagnostics and staging tools, improving the ability to monitor disease over time, enabling earlier intervention, and creating new therapeutic and preventive options. The announcement is therefore well suited to companies working at the intersection of biomedical R and D and product development, such as firms building diagnostic platforms, imaging or sensing technologies, biomarker assays, decision-support tools, device-based approaches, or candidate therapeutics aimed at liver disease pathways.
In terms of funding mechanism, this FOA uses the SBIR R43/R44 structure and accepts Phase I, Phase II, and Fast Track applications. Phase I typically supports early feasibility and proof-of-concept development, Phase II supports further development and validation toward commercialization, and Fast Track allows applicants to propose a combined Phase I/Phase II plan under a single application when the project is ready for an accelerated path. The FOA also notes it runs in parallel with a companion announcement of identical scientific scope for the Small Business Technology Transfer (STTR) program (PAR 09 094, using R41/R42 mechanisms), which is relevant for teams that require a formal small business-academic research partner structure under STTR rules.
Eligibility is limited to small businesses, and there is no cost sharing or matching requirement. The number of awards and total dollars are not predetermined; awards depend on the availability of funds and on whether enough high-quality, meritorious applications are received. In other words, funding outcomes hinge primarily on scientific and technical merit, the credibility of the development plan, and the appropriateness of the proposed budget and timeline.
Key administrative details from the source listing include that the opportunity is categorized as a discretionary grant program administered by NIH, posted February 11, 2009, with an original and current closing date of January 7, 2012 (and archived February 7, 2012). The listing is associated with multiple CFDA numbers spanning environmental health, alcohol research, drug abuse, technological innovations to improve human health, cancer research (cause, detection, treatment), and diabetes/digestive/kidney diseases extramural research, reflecting how liver disease research intersects with many NIH mission areas. The full announcement was hosted at grants.nih.gov under PA 09 095, and the NIH Office of Extramural Research (OER) webmaster contact is provided for access or linking issues.
Frequently Asked Questions (FAQs): New Technologies for Liver Disease SBIR (R43/R44) - PA 09 095
What is the New Technologies for Liver Disease SBIR (R43/R44) opportunity?
This opportunity (Funding Opportunity Number PA 09 095) is a National Institutes of Health (NIH) Small Business Innovation Research (SBIR) grant program focused on moving practical, high-impact liver disease innovations toward usable products and enabling technologies. It emphasizes development-oriented work that can produce tangible tools, methods, or therapeutics that improve how liver diseases are detected, tracked, treated, and prevented.
What is the main goal of this funding opportunity?
The main goal is to mobilize the small business community to translate scientific and engineering advances into practical innovations for liver disease that align with clinical and public health needs. The program is designed to bring small businesses into the liver disease R&D pipeline and advance technologies and interventions consistent with the trans-NIH Action Plan for Liver Disease Research.
What types of projects are within the scope of PA 09 095?
The scope is broad and flexible. It supports development of resources, research tools, instrumentation, biomarkers, devices, drugs, and other novel approaches intended to improve diagnosis, monitoring, management, treatment, or prevention of liver diseases.
Does this FOA focus on basic research or product development?
While it builds on scientific and engineering advances, the emphasis is on development-oriented efforts rather than basic research alone. Proposed work is expected to translate advances into usable products or enabling technologies that address real-world liver disease needs.
What diagnostic and biomarker areas are highlighted as priorities?
The FOA highlights reliable and practical diagnostic methods and biomarkers that reflect liver disease activity and stage. It also calls out noninvasive testing approaches, especially those that measure inflammation, fibrosis (scarring), and fat in the liver.
Are noninvasive liver testing approaches specifically encouraged?
Yes. The description specifically highlights noninvasive testing approaches, particularly those aimed at measuring inflammation, fibrosis, and fat in the liver, which are common and clinically important features across many liver conditions.
What kinds of therapeutic development are supported?
The opportunity supports development of drugs and other therapeutic strategies, including biologics and molecular reagents. It also allows complementary and alternative modalities, as long as the application is positioned as a credible development effort aimed at liver disease therapy or prevention.
Can prevention-focused technologies or interventions be proposed?
Yes. In addition to tools for diagnosis and monitoring, the FOA supports development efforts intended to improve prevention of liver diseases, including interventions positioned toward prevention outcomes.
What liver disease needs is NIH trying to address through this program?
Based on the description, NIH is seeking innovations that improve detection and staging, strengthen the ability to monitor disease over time, enable earlier intervention, and create new therapeutic and preventive options for liver disease.
What types of small businesses are a good fit for this opportunity?
The FOA is well suited to companies working at the intersection of biomedical R&D and product development, including firms developing diagnostic platforms, imaging or sensing technologies, biomarker assays, decision-support tools, device-based approaches, or candidate therapeutics focused on liver disease pathways.
What SBIR mechanisms and application types does PA 09 095 accept?
This FOA uses the SBIR R43/R44 structure and accepts Phase I, Phase II, and Fast Track applications.
What is the difference between Phase I, Phase II, and Fast Track under this FOA?
Phase I typically supports early feasibility and proof-of-concept development. Phase II supports further development and validation toward commercialization. Fast Track allows a combined Phase I/Phase II plan to be proposed under a single application when a project is ready for an accelerated path.
Is there a related STTR opportunity with the same scientific scope?
Yes. The FOA runs in parallel with a companion announcement of identical scientific scope for the Small Business Technology Transfer (STTR) program: PAR 09 094, using the R41/R42 mechanisms.
When might an applicant consider the STTR companion announcement instead of this SBIR FOA?
The listing notes that the STTR companion is relevant for teams that require a formal small business-academic research partner structure under STTR rules.
Who is eligible to apply to PA 09 095?
Eligibility is limited to small businesses.
Is cost sharing or matching required?
No. The FOA states there is no cost sharing or matching requirement.
How many awards will NIH make, and how much funding is available?
The number of awards and total dollars are not predetermined. Awards depend on the availability of funds and on whether a sufficient number of high-quality, meritorious applications are received.
What factors most influence whether an application is funded?
Based on the description, funding outcomes hinge primarily on scientific and technical merit, the credibility of the development plan, and the appropriateness of the proposed budget and timeline, along with the availability of funds.
What type of grant program is this, and who administers it?
The opportunity is categorized as a discretionary grant program administered by the National Institutes of Health (NIH).
When was the opportunity posted, and what are the closing dates shown in the listing?
The listing indicates it was posted on February 11, 2009. It shows an original and current closing date of January 7, 2012, and it was archived on February 7, 2012.
Where was the full announcement hosted?
The full announcement was hosted at grants.nih.gov under PA 09 095.
What CFDA numbers are associated with this listing, and what do they suggest?
The listing is associated with multiple CFDA numbers spanning environmental health, alcohol research, drug abuse, technological innovations to improve human health, cancer research (cause, detection, treatment), and diabetes/digestive/kidney diseases extramural research. This reflects that liver disease research intersects with multiple NIH mission areas.
Is there an NIH contact mentioned for technical issues accessing the announcement?
Yes. The listing notes that the NIH Office of Extramural Research (OER) webmaster contact is provided for access or linking issues.
Browse more opportunities from the same category: Education Environment Food and Nutrition Health
Next opportunity: Alcohol, Decision Making and Adolescent Brain Development (R21)
Previous opportunity: DTRA FY2009 2011 Basic Research for Combating Weapons of Mass Destruction (WMD) Broad Agency Announcement (BAA)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 09 095
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 09 095) also looked into and applied for these:
| Funding Opportunity |
|---|
| New Technologies for Liver Disease STTR (R41/R42) Apply for PA 09 094 Funding Number: PA 09 094 Agency: National Institutes of Health Category: Education Environment Food and Nutrition Health Funding Amount: Case Dependent |
| Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral MD/PhD and Other Dual Doctoral Degree Fellows (F30) Apply for PA 09 207 Funding Number: PA 09 207 Agency: National Institutes of Health Category: Education Environment Food and Nutrition Health Funding Amount: Case Dependent |
| Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral MD/PhD and Other Dual Doctoral Degree Fellows (Parent F30) Apply for PA 10 107 Funding Number: PA 10 107 Agency: National Institutes of Health Category: Education Environment Food and Nutrition Health Funding Amount: Case Dependent |
| Structural Biology of Membrane Proteins (R01) Apply for PA 10 228 Funding Number: PA 10 228 Agency: National Institutes of Health Category: Education Environment Food and Nutrition Health Funding Amount: Case Dependent |
| Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral MD/PhD and Other Dual Doctoral Degree Fellows (Parent F30) Apply for PA 11 110 Funding Number: PA 11 110 Agency: National Institutes of Health Category: Education Environment Food and Nutrition Health Funding Amount: Case Dependent |
| Ruth L. Kirschstein National Research Service Awards (NRSA) for Individual Postdoctoral Fellows (Parent F32) Apply for PA 11 113 Funding Number: PA 11 113 Agency: National Institutes of Health Category: Education Environment Food and Nutrition Health Funding Amount: Case Dependent |
| Ruth L. Kirschstein National Research Service Award Short Term Institutional Research Training Grants (Parent T35) Apply for PA 11 185 Funding Number: PA 11 185 Agency: National Institutes of Health Category: Education Environment Food and Nutrition Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 09 095", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.